PAST Rx will Mitigate Risk

PAST’s Solution Improves PDMP Data

Most patients are not abusing or diverting their pain-killers. Some are. State PDMPs are supposed to help prescribers figure out which ones… but that has proven difficult and time-consuming. Our solution – PASTRx – significantly improves PDMP data, quickly helping eliminate or validate suspicion,  to help providers more confidently decide what medication should be or not be prescribed… not constrained by caution or policy.

Under the guidance of pain management practitioners who were frustrated by the time and effort necessary to derive support for clinical decisions from PDMP data, plus the support of several states and grants, we have developed the extremely affordable PASTRx system.

PASTRx Aggregates Multiple Data Sources

PASTRx aggregates PDMP data with additional sources, such as the CDC, NIH, & GeoMapping, and then applies unique algorithms and advanced visualization technology to analyze and interpret all the data, and then we produce and quickly deliver, within the clinical workflow, easily interpreted, graphical views of patients’ Controlled Substance prescription history faster, easier and more valuable than PDMPs alone.

PASTRx also includes four brief Risk Assessment Instruments, each for a specific type of patient and done in a couple of minutes, which will help providers determine if that patient is at risk for potential abuse or misuse of the pain medication that might be or has been prescribed. The AMA has reported that the administration of one of these instruments has allowed the submission of an amended E/M service for increased reimbursement.

P.A.S.T. will always be able to certify that a PASTRx report on a specific patient was produced for a particular requestor on a specific date. Note: we do not maintain data with names.

More Valuable than PDMPs Alone

PASTRx Clinical Decision Support more valuable than PDMPs alone:

  • Quickly and definitively substantiate or eliminate suspicion when treating new, even established patients presenting with pain
  • Documentation & Reports for Management and Inquiry
  • Help providers comply with Professional Guidelines & the Law
  • Reduce Risk and Protect Patients and Providers
  • Potential incremental revenue

Follow Prescription Advisory

A study was conducted to estimate the societal costs of prescription opioid abuse, dependence, and misuse in the United States. Costs were grouped into three categories: health care, workplace, and criminal justice.

The results: Total US societal costs of prescription opioid abuse were estimated at $55.7 billion in 2007 (USD in 2009). Workplace costs accounted for $25.6 billion, health care costs accounted for $25.0 billion, and criminal justice costs accounted for $5.1 billion. Workplace costs were driven by lost earnings from premature death ($11.2 billion) and reduced compensation/lost employment ($7.9 billion).

Conclusions: The costs of prescription opioid abuse represent a substantial and growing economic burden for the society. The increasing prevalence of abuse suggests an even greater societal burden in the future.

Pain Medicine, Volume 12, Issue 4, April 2011

PDMPs have many limitations in their current format, including complex access issues, timeliness, and whether the data are presented to the physician automatically or require physician effort to retrieve.

ACEP - Annals of Emergency Medicine – 525
Prescription Advisory Systems & Technology

Request a PastRx Demo

We will contact you to arrange a demo at your convenience.

You have Successfully Subscribed!

Prescription Advisory Systems & Technology

Contact PastRx

A representive will be in touch to answer any questions or concerns you might have.

Thank you! A Prescription Advisory representative will contact you shortly.

Share This